Literature DB >> 16914563

Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.

Beverly Moy1, Paul E Goss.   

Abstract

Endocrine therapy is widely accepted as the most important treatment for all patients with hormone receptor-positive breast cancer. However, despite the positive effect of endocrine therapy on clinical outcome, resistance to these drugs inevitably develops. This article reviews the problem of resistance to hormonal therapy and addresses potential approaches to overcome intrinsic or acquired mechanisms of resistance.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16914563     DOI： 10.1158/1078-0432.CCR-06-1535

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  27 in total

1.  Regulation of aromatase induction by nuclear receptor coregulator PELP1.

Authors:  Ratna K Vadlamudi; Rajib Rajhans; Dimple Chakravarty; Binoj C Nair; Sujit S Nair; Dean B Evans; Shiuan Chen; Rajeshwar Rao Tekmal
Journal:  J Steroid Biochem Mol Biol       Date:  2009-09-30       Impact factor: 4.292

Review 2.  Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.

Authors:  Michael Gnant; Richard Greil; Michael Hubalek; Günther Steger
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

Review 3.  What do we know about the mechanisms of aromatase inhibitor resistance?

Authors:  Shiuan Chen; Selma Masri; Xin Wang; Sheryl Phung; Yate-Ching Yuan; Xiwei Wu
Journal:  J Steroid Biochem Mol Biol       Date:  2006-10-19       Impact factor: 4.292

4.  Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.

Authors:  Nitin Telang; Hareesh B Nair; George Y C Wong
Journal:  Biomed Rep       Date:  2019-10-03

5.  MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Authors:  George C Bobustuc; Joshua S Smith; Sreeram Maddipatla; Sheila Jeudy; Arati Limaye; Beth Isley; Maria-Lourdes M Caparas; Susan M Constantino; Nikita Shah; Cheryl H Baker; Kalkunte S Srivenugopal; Said Baidas; Santhi D Konduri
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

Review 6.  Postoperative endocrine therapy for invasive breast cancer.

Authors:  Leisha A Emens; Nancy E Davidson
Journal:  Cancer Treat Res       Date:  2009

7.  Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.

Authors:  Rajib Rajhans; Hareesh B Nair; Sujit S Nair; Valerie Cortez; Kijima Ikuko; Nameer B Kirma; Dujin Zhou; Alan E Holden; Darrell W Brann; Shiuan Chen; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Endocrinol       Date:  2007-12-13

8.  Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.

Authors:  Xinyan Wu; Muhammad Saddiq Zahari; Santosh Renuse; Raja Sekhar Nirujogi; Min-Sik Kim; Srikanth S Manda; Vered Stearns; Edward Gabrielson; Saraswati Sukumar; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2015-09-01       Impact factor: 5.911

9.  Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.

Authors:  Jatin K Nagpal; Sujit Nair; Dimple Chakravarty; Rajib Rajhans; Saikumar Pothana; Darrell W Brann; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

Review 10.  Current research topics in endocrine therapy for breast cancer.

Authors:  Hiroko Yamashita
Journal:  Int J Clin Oncol       Date:  2008-10-23       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.